| [1] |
Paik S,Bryant J,Park C,et al.ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive,hormone receptor-negative breast cancer.J Natl Cancer Inst,1998,90:1361-1370.
|
| [2] |
陈强,叶韵斌,吴 凡.HER-2 单抗曲妥珠单克隆抗体耐药机制研究进展.[2009-11-20] .http://reg.csco.org.cn/reg2007/main/200706.pdf.
URL
|
| [3] |
Antonio C,Wolff M,Elizabeth H,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.J Clin Oncol,2007,25:118-145.
|
| [4] |
Rakkhit R,Broglio K,Peintinger F,et al.Significant increased recurrence rates among breast cancer patients with HER-2-positive,T1a,b N0 M0 tumors.San Antonio Breast Cancer Symposium Proceedings,San Antonio,Texas,USA,2008.[2009-11-20] .http://www.abstracts2view.com/sabcs/search.php?.
URL
|
| [5] |
Tovey SM,Marla S,Brown S,et al.Poor survival outcomes in HER-2 positive breast cancer patients with low grade,node negative tumours:implications for trastuzumab therapy?San Antonio Breast Cancer Symposium Proceedings,San Antonio,Texas,USA,2008.[2009-11-20] .http://www.abstracts2view.com/sabcs/search.php?.
URL
|
| [6] |
Robert W,Benjamin O,Stephen B,et al.NCCN Clinical Practice Guidelines in Oncology TM Breast Cancer V.1.2009.[2009-11-20] .http://www.nccn.org.
URL
|
| [7] |
Gianni L,Eiermann W,Semiglazov V,et al.Neoadjuvant trastuzumab in patients with HER-2-positive locally advanced breast cancer:primary efficacy analysis of the NOAH trial.San Antonio Breast Cancer Symposium Proceedings,San Antonio,Texas,USA,2008.[2009-11-20] .http://www.abstracts2view.com/sabcs/search.php?
URL
|
| [8] |
Rugo H,Kaufman P,Tan Chiu E,et al.Survival of patients with HER-2(+)metastatic breast cancer and use of trastuzumab following progression:analysis of regist HER.San Antonio Breast Cancer Symposium Proceedings,San Antonio,Texas,USA,2008.[2009-11-20] .http://www.abstracts2view.com/sabcs/search.php?.
URL
|
| [9] |
Portera CC,Walshe JM,Rosing DR,et al.Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] .human epidermal growth factor receptor 2-positive metastatic breast cancer.Clin Cancer Res,2008,14:2710-2716.
|
| [10] |
Muehlbauer S,Revil C,LeylandJones B,et al.Pooled cardiac safety analysis of patients with HER-2-positive metastatic breast cancer receiving trastuzumab.San Antonio Breast Cancer Symposium Proceedings,San Antonio,Texas,USA,2008.[2009-11-20] .http://www.abstracts2view.com/sabcs/search.php?.
URL
|
| [11] |
Jackisch C,Hinke A,Schoenegg W,et al.Trastuzumab treatment in elderly patients with advanced breast cancer(ABC)-results from a large observational study.San Antonio Breast Cancer Symposium Proceedings,San Antonio,Texas,USA,2008.[2009-11-20] .http://www.abstracts2view.com/sabcs/search.php?.
URL
|
| [12] |
Untch M,Gelber RD,Jackisch C,et al.Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.Ann Oncol,2008,19:1090-1096.
|
| [13] |
Jahanzeb M.Adjuvant trastuzumab therapy for HER-2-positive breast cancer.Clin Breast Cancer,2008,8:324-333.
|
| [14] |
Spielmann M,Roché H,Delozier T,et al.Trastuzumab for patients with axillary-node-positive breast cancer:results of the FNCLCC-PACS 04 Trial.J Clin Oncol,2009,27:6129-6134.
|